Inhibitors of GPR174 and Uses Thereof
GPR174 is an orphan receptor that has been implicated in cancer, nervous system diseases and disorders and neuroregeneration. We have identified inhibitors of GPR174 and have identified the G-protein signaling pathways that GPR174 modulates. Based on this discovery, the present invention features methods for inhibiting GPR174 activity and thereby stimulating an immune response in a subject in need thereof, particularly in the use of treatment of non-malignant neoplasms, malignant neoplasms (i.e., cancer), nervous system diseases and disorders and neuroregeneration, as well as related compositions.
1 . A method of stimulating an immune response in a mammalian patient in need thereof comprising administering to the mammalian patient a therapeutically effective amount of a small molecule inhibitor of GPR174 signaling.
2 . The method of claim 1 , wherein the GPR174 signaling comprises Gs signaling.
3 . The method of claim 1 , wherein the small molecule inhibitor is an inverse agonist of GPR174 signaling.
4 . The method of claim 1 , wherein the small molecule inhibitor is an antagonist of GPR174 signaling.
5 . The method of claim 1 , wherein the small molecule inhibitor inhibits LysoPS or pepducin dependent activation of GPR174 signaling in a cell expressing GPR174 by at least 25%.
6 . The method of claim 1 , wherein the stimulated immune response comprises a T-cell-mediated immune response.
7 . The method of claim 6 , wherein the T-cell mediated immune response comprises suppression of T-Reg activity, differentiation, growth and/or proliferation.
8 . The method of claim 6 , wherein the T-cell mediated immune response comprises stimulation of Teffector activity, differentiation, growth and/or proliferation.
9 . The method of claim 6 , wherein the T-cell mediated immune response comprises stimulation of Th1 cell activity, differentiation, growth and/or proliferation.
10 . The method of claim 6 , wherein the T-cell mediated immune response comprises suppression of Th17 cell activity, differentiation, growth and/or proliferation.
11 . The method of claim 1 , wherein the stimulated immune response comprises a reduction in immune-cell or cancer-cell associated programmed death-ligand 1 (PD-L1) expression or cytotoxic T-lymphocyte-associated antigen 4 (CTLA4) expression or T cell immunoreceptor with Ig and ITIM domains (TIGIT) expression or amphiregulin (AREG) expression.
12 . The method of claim 1 , wherein the stimulated immune response comprises an NK-cell mediated immune response.
13 . The method of claim 1 , wherein at least a portion of the T-cells or the NK-cells express GPR174.
14 . The method of claim 1 , wherein the patient is suffering from, or harboring a neoplasm not recognized by the body as self.
15 . The method of claim 14 , wherein the neoplasm is a non-malignant tumor.
16 . The method of claim 1 , wherein the patient is a cancer patient.
17 . The method of claim 16 , wherein the cancer is a solid tumor.
18 . The method of claim 16 , wherein the cancer is a blood cancer.
19 . The method of claim 14 , wherein the tumor is infiltrated with lypmphocyte cells that express GPR174.
20 . The method of claim 1 , wherein the GPR174 has 90% or greater sequence identity to SEQ ID NO:1.
21 . The method of claim 1 , wherein the mammalian patient is a human.
22 . The method of claim 1 , wherein T-cell activity, differentiation, proliferation, and/or growth is stimulated in a population of peripheral blood mononuclear cells (PBMCs) contacted with the small molecule inhibitor as compared to a control population of PBMCs not contacted with the small molecule inhibitor.
23 . The method of claim 1 , wherein T-reg activity, differentiation, proliferation, and/or growth is decreased or inhibited in a population of peripheral blood mononuclear cells (PBMCs) contacted with the small molecule inhibitor as compared to a control population of PBMCs not contacted with the small molecule inhibitor.
24 . The method of claim 1 , wherein the fraction of FoxP3 + Helios+ T-cells (regulatory T-cells) is decreased by at least 20% in a population of PBMCs contacted with the small molecule inhibitor as compared to a control population of PBMCs not contacted with the small molecule inhibitor.
25 . The method of 1 , wherein the level of cAMP is decreased by at least 20% in a cell expressing GPR174 contacted with the small molecule inhibitor as compared to a control cell expressing GPR174 not contacted with the small molecule inhibitor.
26 . The method of claim 1 , wherein the activity of protein kinase A is decreased by at least 20% in cells expressing GPR174 contacted with the small molecule inhibitor as compared to a control cell not contacted with the small molecule inhibitor.
27 . The method of claim 1 , wherein the production of one or more of IL-2, INF-γ, TNF-α, IL-6, and IL-10 is increased by at least 20% in peripheral blood mononuclear cells (PBMCs) contacted with the small molecule inhibitor as compared to control cells not contacted with the small molecule inhibitor.
28 . The method of claim 1 , wherein the production of IL-17A is decreased by at least 20% in PBMCs contacted with the small molecule inhibitor as compared to control cells not contacted with the small molecule inhibitor.